2018 APSR Congress
Sponsored symposia
This page has been reproduced from the website of the
2018 APSR Congress in Tapei, Taiwan
30 November 2018 (Friday) 12:45-13:45 Room 201ABC, 2F
Lunch Symposium 1
Time for new treatment paradigm in milder asthma? (AstraZeneca Taiwan)
Chair: Diahn-Warng Perng (Taiwan)
| LS01-1 | Overuse of SABA and underuse of ICS in milder asthma - the asthma paradox Eric Bateman (South Africa) |
| LS01-2 | Challenges in the treatment of patients with milder asthma in Taiwan and Asia Ping-Hung Kuo (Taiwan) |
30 November 2018 (Friday) 12:45-13:45 Room 201DEF, 2F
Lunch Symposium 2
Progressive pulmonary fibrosis: current and future perspectives (Boehringer Ingelheim International GmbH)
Chair: Meng-Chih Lin (Taiwan)
Chair: Athol Wells (United Kingdom)
| LS02-1 | Diagnosis of IPF: guidelines and practice Athol Wells (United Kingdom) |
| LS02-2 | Optimal use of antifibrotic therapies in IPF Martin Kolb (Canada) |
| LS02-3 | Ongoing research in progressive fibrosing ILDs Luca Richeldi (Italy) |
30 November 2018 (Friday) 12:45-13:45 Room VIP, 4F
Lunch Symposium 3
REALISEing the Power of Transformative RWEs (Mundipharma)
Chair: Hao-Chien Wang (Taiwan)
| LS03-1 | Tailoring asthma management to your patients: Realizations from REALISE ASIA Aileen David Wang (Philippines) |
| LS03-2 | What is TRANSFORMing Asthma Practice: DPI, pMDI or upcoming Breath Triggered Inhalers? Chin Kook Rhee (Republic of Korea) |
| LS03-3 | How will exacerbation rates from RWEs impact your practice? Dato Abdul Razak Abdul Muttalif (Malaysia) |
30 November 2018 (Friday) 12:45-13:45 Room 103, 1F
Lunch Symposium 4
NIV management for COPD (ResMed)
Chair: Naricha Chirakalwasan (Thailand)
Chair: Ning-Hung Chen (Taiwan)
| LS04-1 | Overview of NIV management in Asia Ning-Hung Chen (Taiwan) |
| LS04-2 | From Hospital to Home - NIV Management for COPD Patient Mark William Elliott (UK) |
30 November 2018 (Friday) 12:45-13:45 Room 105, 1F
Lunch Symposium 5
Optimize the clinical benefit of chemotherapy for NSCLC (Eli Lilly)
Chair: Chong-Jen Yu (Taiwan)
Chair: Jin-Yuan Shih (Taiwan)
| LS05-1 | Alimta real world data from Taiwan NHIRD Te-Chun Hsia (Taiwan) |
| LS05-2 | The role of antiangiogenic drug in hard to treat NSCLC Egbert Smit (Netherlands) |
30 November 2018 (Friday) 17:45-18:45 Room 103, 1F
Evening Symposium 1
The Unprecedented Overall Survival Benefits for advanced NSCLC by Anti-PD-1 in 1L (MSD Taiwan)
Chair: Chong-Jen Yu (Taiwan)
| ES01-1 | The Unprecedented Overall Survival Benefits for advanced NSCLC by Anti-PD-1 in 1L Steven Kao (Australia) |
| ES01-2 | TBC TBC |
1 December 2018 (Saturday) 12:45-13:45 Room 201ABC, 2F
Lunch Symposium 6
Focus on Reducing OCS in Severe Asthma - the Why and the How? (AstraZeneca Taiwan)
Chair: Sang-Heon Kim (Republic of Korea)
| LS06-1 | Insights into the cumulative burden of OCS exposure Sang-Heon Kim (Republic of Korea) |
| LS06-2 | Understanding the patients experience and the impact of OCS use V McDonald (Australia) |
| LS06-3 | Strategies to reduce OCS use and exposure in the era of biologic agents J Upham (Australia) |
1 December 2018 (Saturday) 12:45-13:45 Room 201DEF, 2F
Lunch Symposium 7
Breaking paradigms: Treatment evolution in asthma (GSK)
Chair: Shu-Min Lin (Taiwan)
| LS07-1 | The ICS/LABA experience : any new update? Norbert Berend (Australia) |
| LS07-2 | Challenges in severe asthma : the role of new biologics Frank Albers (USA) |
1 December 2018 (Saturday) 12:45-13:45 Room VIP, 4F
Lunch Symposium 8
COPD (Chiesi and OEP)
Chair: Chong-Jen Yu (Taiwan)
| LS08-1 | Topic related to small airways dysfunction in COPD Kang-Yun Lee (Taiwan) |
| LS08-2 | Extra-fine benefit in COPD Dave Singh (UK) |
1 December 2018 (Saturday) 12:45-13:45 Room 102, 1F
Lunch Symposium 9
Practical, personalized care: A tailored approach to management of COPD (Boehringer Ingelheim International GmbH)
Chair: Diahn-Warng Perng (Taiwan)
Chair: David M.G. Halpin (UK)
| LS09-1 | COPD care in Asia: Current perspectives, future directions Diahn-Warng Perng (Taiwan) |
| LS09-2 | Building on strong foundations: The importance of inhaler choice in COPD Omar Usmani (UK) |
| LS09-3 | Mapping the role of ICS: Building on the latest insights in COPD Marc Miravitlles (Spain) |
| LS09-4 | Steering the course: What outcomes matter most for our patients? David M.G. Halpin (UK) |
1 December 2018 (Saturday) 12:45-13:45 Room 103, 1F
Lunch Symposium 10
Recent advances in preventing exacerbations of COPD (Novartis)
Chair: Wu-Huei Hsu (Taiwan)
Chair: Horng-Chyuan Lin (Taiwan)
| LS10-1 | The Science of COPD Exacerbations: Time to take it personally Jadwiga Wisia Wedzicha (UK) |
| LS10-2 | Topic Preventing COPD exacerbations: Pharmacotherapeutic approaches in 2018 Kenneth R. Chapman (Canada) |
1 December 2018 (Saturday) 12:45-13:45 Room 105, 1F
Lunch Symposium 11
Future ALK NSCLC treatment landscape (Novartis)
Chair: Jin-Yuan Shih (Taiwan)
| LS11-1 | The role of NGS in determining sequential treatment for ALK-positive NSCLC David Planchard (France) |
| LS11-2 | Updated treatment strategy for BRAF mutant NSCLC and real world experience from France David Planchard (France) |
| LS11-3 | Classification and management of neuroedocrine tumor in lung Te-Chun Hsia (Taiwan) |
1 December 2018 (Saturday) 17:45-18:45 Room 201ABC, 2F
Evening Symposium 2
Asthma (OEP)
Chair: Jubert Benedicto (Philippine)
| ES02-1 | Topic related to small airways dysfunction in Asthma (TBC) Diahn-Warng Perng (Taiwan) |
| ES02-2 | Real-life study of Extra-fine formulation in Asthma David Price (UK) |
1 December 2018 (Saturday) 17:45-18:45 Room 201DEF, 2F
Evening Symposium 3
Individualizing the therapeutic strategy in COPD (GSK)
Chair: Meng-Chih Lin (Taiwan)
| ES03-1 | COPD facts and gaps in Asia-Pacific Horng-Chyuan Lin (Taiwan) |
| ES03-2 | The role of the Ellipta portfolio Paul Jones (UK) |
1 December 2018 (Saturday) 17:45-18:45 Room VIP, 4F
Evening Symposium 4
Roche satellite symposium of Cancer ImmunoTherapy in Lung Cancer (Roche)
Chair: Gee-Chen Chang (Taiwan)
| ES04-1 | Activate the POWER- clinical advances of atezolizumab in lung cancer Leora Horn (USA) |
| ES04-2 | Cancer Immunotherapy in EGFR+ patients Shih-Hsin Hsiao (Taiwan) |
1 December 2018 (Saturday) 17:45-18:45 Room 103, 1F
Evening Symposium 5
The asthma patient journey: What more can be done? (Novartis)
Chair: Kang-Yun Lee (Taiwan)
Chair: Shih-Lung Cheng (Taiwan)
| ES05-1 | Phenotype/endotype in severe asthma patients Kian Fan Chung (UK) |
| ES05-2 | Current options for severe asthma treatment and what's on the horizon? Po-Jui Chang (Taiwan) |
1 December 2018 (Saturday) 17:45-18:45 Room 105, 1F
Evening Symposium 6
A Paradigm shift in the treatment of locally advanced and advanced NSCLC (AstraZeneca Taiwan)
Chair: James Yang (Taiwan)
| ES06-1 | Evolving decisions and best practices in the management of EGFR M+ NSCLC Suresh S. Ramalingam (USA) |
| ES06-2 | Incoporating multimodality strategy in locally advanced NSCLC Chao-Chi Ho (Taiwan) |
